Liberia & Sierra Leone, both primary epicenters of the supposed Ebola outbreak, were recently subject to the “largest ever Yellow Fever Immunization Program” conducted in that region – an estimated 12 million locals impacted (infected) by the compound shot.
The epidemiology of Yellow Fever also bares striking resemblance to Ebola, given the distinct characteristics & potential virulence common to each virus:
1. an incubation period lasting upwards of 1 week (‘Physical symptoms usually appear 3–6 days after’)
2. an array of flu-like symptoms during the initial stages, including (‘fever, muscle pain, particularly backache, headache, shivering, loss of appetite, and nausea or vomiting’)
3. leading to varying degrees of internal “blackish” bruising & widespread hemorrhaging (‘gastrointestinal bleeding, haematuria, skin petechiae, ecchymoses,’)
4. followed by rapid systemic deterioration, marked by Kidney failure, often leading to death (‘About 20%–50% of patients with hepato-renal failure die, usually 7–10 days after the onset of disease’)
‘Typically, the disease onset is abrupt, with fever, muscle pain, particularly backache, headache, shivering, loss of appetite, and nausea or vomiting. Congestion of the conjunctivae and face are common, as well as relative bradycardia in the presence of fever. The patient is usually viraemic during this period, which lasts for approximately 3–6 days.
In approximately 15% of infected persons, the illness recurs in more severe form after a brief remission of 2–24 hours.11 Symptoms include fever, nausea, vomiting, epigastric pain, jaundice, renal insufficiency, and cardiovascular instability. A bleeding diathesis can occur causing gastrointestinal bleeding, haematuria, skin petechiae, ecchymoses, epistaxis, and bleeding from the gums and needle-puncture sites.
Physical findings include scleral and dermal jaundice, haemorrhages at different sites and epigastric tenderness without hepatic enlargement. The haemorrhagic manifestations are caused by reduced synthesis of clotting factors as well as by a consumptive coagulopathy.
About 20%–50% of patients with hepato-renal failure die, usually 7–10 days after the onset of disease. Patients surviving YF may experience prolonged weakness and fatigue, but healing of the liver and kidney injuries is usually complete.‘ Vaccines and vaccination against yellow fever/WHO Position Paper – June 2011
‘Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event associated with administration of the yellow fever vaccine. YEL-AVD is an illness similar to wild-type yellow fever, in which the vaccine virus proliferates in multiple organs, causing multiple organ dysfunction syndrome or multiorgan failure and death in at least 60% of cases. Initial symptoms of YEL-AVD are nonspecific and can include the following: fever, malaise, headache, myalgia, vomiting, and diarrhea. More severe cases can progress to hepatic, renal, or respiratory insufficiency or failure; hypotension; thrombocytopenia; and coagulopathy (inability to regulate clotting causing massive hemorrhaging).‘ CDC – History, Epidemiology, and Vaccination Information
‘Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is clinically indistinguishable from wild-type yellow fever illness. Most YEL-AVD reports describe patients with fever and multiple organ system failure, and often death (17 deaths/29 cases worldwide).‘ The American Journal of Tropical Medicine and Hygiene
No Government is going to force another toxic, experimental Vaccine & medley of debilitating Drugs on our communities to combat a clearly manufactured Ebola crisis...not on my watch. We've been here before. History is predictably repeating itself…again.
Coming soon - VRM: The Ebola Report